TY - JOUR
T1 - Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma
AU - Ghanem, M. A.
AU - Van Steenbrugge, G. J.
AU - Sudaryo, Mondastri Korib
AU - Mathoera, R. B.
AU - Nijman, J. M.
AU - Van Der Kwast, Th H.
N1 - Funding Information:
This study was supported by the ‘Fondo de Investigación Sanitaria-Instituto de Salud Carlos III’ [ PI15/00186 and PI18/00050 to I.I.C., and PI13/01512 , PI16/00201 an PIE15/00065 to F.G.G.]; and the European Regional Development Fund/European Social Fund FIS [FEDER/FSE, Una Manera de Hacer Europa]. MINECO funds support R.R. and O.P. contracts through and RTC-2016-5314-1 project. The funding sources did not provide any input in the development of the research and manuscript.
Funding Information:
This study was supported by the ?Fondo de Investigaci?n Sanitaria-Instituto de Salud Carlos III? [PI15/00186 and PI18/00050 to I.I.C., and PI13/01512, PI16/00201 an PIE15/00065 to F.G.G.]; and the European Regional Development Fund/European Social Fund FIS [FEDER/FSE, Una Manera de Hacer Europa]. MINECO funds support R.R. and O.P. contracts through and RTC-2016-5314-1 project. The funding sources did not provide any input in the development of the research and manuscript.
PY - 2003/2/1
Y1 - 2003/2/1
N2 - Aims: To investigate the prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor Flt-1 in nephroblastoma and whether tumour microvessel density (MVD) immunoreactivity, determined by the CD31 antigen, is related to the expression of VEGF and Flt-1. Methods: The expression of VEGF and Flt-1 and MVD were investigated by means of immunohistochemical analysis in 62 Wilms's tumours. Patients were treated preoperatively with chemotherapy and had a mean follow up of 5.7 years. Results: In general, VEGF and Flt-1 were expressed in normal kidney parenchyma and to a variable extent in the three main components of Wilms's tumour, namely: the blastemal, epithelial, and stromal cells. In tumour tissue, 52% and 47% of blastemal cells were positive for VEGF and Flt-1, respectively. A non-significant correlation was found between the expression of VEGF and Flt-1 in blastemal and epithelial cells and the clinicopathological stage. MVD was significantly higher in VEGF and Flt-1 positive tumours than in VEGF and Flt-1 negative tumours. Univariate analysis showed that the expression of VEGF and Flt-1 in blastemal cells was indicative of clinical progression and tumour specific survival. In addition, MVD expression was indicative of clinical progression. Epithelial staining was of no prognostic value. In a multivariate analysis, VEGF protein expression by blastemal cells was an independent prognostic marker for clinical progression. Conclusions: These results indicate that VEGF and Flt-1 protein expression are closely related to MVD and seem to be an important predictor for poor prognosis in treated patients with Wilms's tumour. Therefore, the expression of these molecules in primary Wilms's tumour may be useful in identifying those patients at high risk of tumour recurrence and in guiding antiangiogenic treatment.
AB - Aims: To investigate the prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor Flt-1 in nephroblastoma and whether tumour microvessel density (MVD) immunoreactivity, determined by the CD31 antigen, is related to the expression of VEGF and Flt-1. Methods: The expression of VEGF and Flt-1 and MVD were investigated by means of immunohistochemical analysis in 62 Wilms's tumours. Patients were treated preoperatively with chemotherapy and had a mean follow up of 5.7 years. Results: In general, VEGF and Flt-1 were expressed in normal kidney parenchyma and to a variable extent in the three main components of Wilms's tumour, namely: the blastemal, epithelial, and stromal cells. In tumour tissue, 52% and 47% of blastemal cells were positive for VEGF and Flt-1, respectively. A non-significant correlation was found between the expression of VEGF and Flt-1 in blastemal and epithelial cells and the clinicopathological stage. MVD was significantly higher in VEGF and Flt-1 positive tumours than in VEGF and Flt-1 negative tumours. Univariate analysis showed that the expression of VEGF and Flt-1 in blastemal cells was indicative of clinical progression and tumour specific survival. In addition, MVD expression was indicative of clinical progression. Epithelial staining was of no prognostic value. In a multivariate analysis, VEGF protein expression by blastemal cells was an independent prognostic marker for clinical progression. Conclusions: These results indicate that VEGF and Flt-1 protein expression are closely related to MVD and seem to be an important predictor for poor prognosis in treated patients with Wilms's tumour. Therefore, the expression of these molecules in primary Wilms's tumour may be useful in identifying those patients at high risk of tumour recurrence and in guiding antiangiogenic treatment.
UR - http://www.scopus.com/inward/record.url?scp=0037313157&partnerID=8YFLogxK
U2 - 10.1136/jcp.56.2.107
DO - 10.1136/jcp.56.2.107
M3 - Article
C2 - 12560388
AN - SCOPUS:0037313157
SN - 0021-9746
VL - 56
SP - 107
EP - 113
JO - Journal of Clinical Pathology
JF - Journal of Clinical Pathology
IS - 2
ER -